| Literature DB >> 23383161 |
Steve R Bischoff1, Shengdar Q Tsai, Nicholas E Hardison, Alison A Motsinger-Reif, Bradley A Freking, Dan J Nonneman, Gary A Rohrer, Jorge A Piedrahita.
Abstract
To gain insight into differences in placental physiology between two swine breeds noted for their dissimilar reproductive performance, that is, the Chinese Meishan and white composite (WC), we examined gene expression profiles of placental tissues collected at 25, 45, 65, 85, and 105 days of gestation by microarrays. Using a linear mixed model, a total of 1,595 differentially expressed genes were identified between the two pig breeds using a false-discovery rate q-value ≤0.05. Among these genes, we identified breed-specific isoforms of XIST, a long non-coding RNA responsible X-chromosome dosage compensation in females. Additionally, we explored the interaction of placental gene expression and chromosomal location by DIGMAP and identified three Sus scrofa X chromosomal bands (Xq13, Xq21, Xp11) that represent transcriptionally active clusters that differ between Meishan and WC during placental development. Also, pathway analysis identified fundamental breed differences in placental cholesterol trafficking and its synthesis. Direct measurement of cholesterol confirmed that the cholesterol content was significantly higher in the Meishan versus WC placentae. Taken together, this work identifies key metabolic pathways that differ in the placentae of two swine breeds noted for differences in reproductive prolificacy.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23383161 PMCID: PMC3561265 DOI: 10.1371/journal.pone.0055345
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Differential placental gene expression in Meishan versus WC swine breeds.
Volcano plots were used to visualize differential expression between Meishan and White Composite placental tissues against level of significance surveyed for breed specific differences. The x-axis is the log2 fold-change difference of the Meishan minus WC breed groups. The vertical axis represents the statistical evidence as a measure of the –log10 transformation of the p-value for each test of differences between samples. Each of the ∼24,000 oligonucleotide probe sets is plotted. A red dashed line indicates the FDR adjustment (approximately q-value <0.05) to correct for multiple testing. Blue dashed lines showed estimates of 1, and −1, which corresponds to a 2-fold (inverse natural logarithm of estimates) increase or decrease respectively.
EvaGreen RT-qPCR analysis of select genes across placental datasets.
| Gene | Gene Description | Probe | Description | Day | N | Std ErrMS | Std ErrWC | Fold Change(MS-WC) | Student |
|
| ATP- | Ssc.7146.A1_a1 | Cholesterol Efflux | 25 | 6 | 0.14 | 0.30 | −6.63 | 3.11E–4 |
| 45 | 6 | 0.10 | 0.21 | −3.65 | 2.55E–3 | ||||
| 65 | 6 | 0.24 | 0.86 | −4.40 | 7.15E–4 | ||||
| 85 | 6 | 0.08 | 0.63 | −5.32 | 6.21E–3 | ||||
| 105 | 6 | 0.17 | 0.60 | −8.15 | 3.955E–3 | ||||
|
| X ( | Ssc.2434.1.A1_at | X-Cs inactivation | 25 | 6 | 0.68 | 0.42 | −1573.8 | 3.08E–02 |
| 45 | 6 | 0.19 | 0.25 | −14.02 | 5.38E–08 | ||||
| 65 | 6 | 0.60 | 0.96 | −138.14 | 4.28E–02 | ||||
| 85 | 6 | 0.31 | 0.69 | −2149.8 | 3.82E–02 | ||||
| 105 | 6 | 0.44 | 0.41 | −576.03 | 1.47E–02 | ||||
|
| X ( | Ssc.31029.1.A1_at | X-Cs inactivation | 25 | 6 | 0.30 | 0.56 | −2.19 | 5.11E–06 |
| 45 | 6 | 0.45 | 1.00 | −1.84 | 1.46E–04 | ||||
| 65 | 6 | 0.59 | 0.95 | −1.12 | 3.56E–02 | ||||
| 85 | 6 | 0.35 | 0.28 | −4.72 | 1.82E–02 | ||||
| 105 | 6 | 0.25 | 0.23 | −1.68 | 3.67E–02 | ||||
|
|
| Ssc.9796.1.A1_at | Genomic Imprinting | 65 | 6 | 0.57 | 0.82 | 2.27 | 1.48E–02 |
|
|
| Ssc.8871.1.S1_at | Genomic Imprinting | 65 | 6 | 0.15 | 0.29 | 1.82 | 4.08E–06 |
|
|
| Ssc.20036.1.S1_at | Internal Reference | 65 | 6 | 0.49 | 0.07 | – | – |
|
|
| Ssc.10553.1.A1_a_at | Internal Reference | 25 | 6 | 0.38 | 0.83 | – | – |
|
|
| Ssc.10553.1.A1_a_at | Internal Reference | 45 | 6 | 0.43 | 0.50 | – | – |
|
|
| Ssc.10553.1.A1_a_at | Internal Reference | 65 | 6 | 0.62 | 0.91 | – | – |
|
|
| Ssc.10553.1.A1_a_at | Internal Reference | 85 | 6 | 0.21 | 0.44 | – | – |
|
|
| Ssc.10553.1.A1_a_at | Internal Reference | 105 | 6 | 0.26 | 0.51 | – | – |
Denotes ΔCt values normalized with RPL18.
Denotes significances p<0.05.
Figure 2XIST structure and transcription in Meishan and WC placentas; expression of a short isoform in the Meishan breed.
Swine XIST was discovered and annotated from reciprocal BLAT with bovine XIST as it is not annotated in the current pig 9.2 genome assembly. (A) Specifically, we identified BAC CH242-76N1 (GI: 219925014) that contained porcine XIST. Biochemical studies involving mutated or truncated XIST transcripts revealed the A-repeat region as the functional element responsible for X-chromosome inactivation [65]. We mapped Affymetrix probesets and the corresponding ESTs to porcine XIST and designed a series of RT-qPCRs (bracketed numbers) to validate microarray results (Table 1). (B) Agarose gel electrophoresis depicting representative PCR assays to amplify regions of genomic DNA or cDNA from D25 MS or WC fetuses for the chromosomal interval SSCX: 58,375,000-58,400,000 based on the assembly (SGSC Sscrofa9.2/susScr2 and BAC CH242-76N1 (GI: 219925014). A postive control for genomic DNA isolation is shown for COL10. For analysis of placental RNA isolation and cDNA generation, we performed reverse-transcription PCR with exon-spanning primers for the positive control RPL18 (Figure 2B, bottom panel, lanes 2+3). The short XIST isoform was absent from additional MS gestations (Table 1).
Figure 3Non-random distribution of Meishan versus WC differentially expressed genes along the X-chromosome.
A bubble plot is depicted for the swine X chromosome (SSCX) in which physical coordinates are plotted (abscissa, x-axis) against sign-ranked –log10(p-values) (ordinate, y-axis). Estimate values from the linear mixed model were used to calculate positive (Meishan) or negative (WC) signs. Each bubble represents a specific probe set printed on the short-oligonucleotide array.
Gene expression and DIGMAP analysis of Sus scrofa chromosome X.
| Band | p-value | Gene | Description |
|
| 2.29E-04 |
| cysteine-rich hydrophobic domain 1 |
|
| discs, large homolog 3 (neuroendocrine-dlg, Drosophila) | ||
|
| interleukin 2 receptor, gamma (severe combined immunodeficiency) | ||
|
| O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) | ||
|
| protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) | ||
|
| ring finger protein 12 | ||
|
| ribosomal protein S4, X-linked | ||
|
| SH3 domain binding glutamic acid-rich protein like | ||
|
| sorting nexin 12 | ||
|
| TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa | ||
|
| X (inactive)-specific transcript | ||
|
| Yip1 domain family, member 6 | ||
|
| zinc finger, MYM-type 3 | ||
|
| 2.94E-02 |
| armadillo repeat containing, X-linked 1 |
|
| alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) | ||
|
| choroideremia (Rab escort protein 1) | ||
|
| cytochrome c oxidase subunit VIIb | ||
|
| nucleosome assembly protein 1-like 3 | ||
|
| poly(A) binding protein, cytoplasmic 5 | ||
|
| sushi-repeat-containing protein, X-linked 2 | ||
|
| 5.05E-02 |
| AT rich interactive domain 4B (RBP1- like) |
|
| calcium/calmodulin-dependent serine protein kinase (MAGUK family) | ||
|
| complement factor properdin | ||
|
| emopamil binding protein (sterol isomerase) | ||
|
| FUN14 domain containing 1 | ||
|
| Krüppel-like factor 8 | ||
|
| melanoma antigen family D, 2 | ||
|
| regucalcin (senescence marker protein-30) | ||
|
| transcription factor binding to IGHM enhancer 3 |
Denotes significant at adjusted p-value <0.05.
Summary of top-ranking common gene ontology (GO) molecular processes in swine placentae.
| Gene Ontology | P-value for MS-WC |
| cholesterol biosynthesis | 0.00001 |
| peroxisome | 0.00001 |
| isoprenoid biosynthesis | 0.00002 |
| pigmentation | 0.00066 |
| nuclear heterochromatin | 0.00082 |
Denotes significance at p<0.05 after multiple correction testing.
Summary of Ingenuity ranked canonical (KEGG) pathways.
| Ingenuity Canonical Pathways | −log(B-H p-value) | Genes |
|
| 4.12 |
|
|
| 2.35 |
|
|
| 2.07 |
|
|
| 1.94 |
|
|
| 1.93 |
|
|
| 1.88 |
|
|
| 1.88 |
|
|
| 1.82 |
|
|
| 1.66 |
|
|
| 1.65 |
|
|
| 1.59 |
|
|
| 1.47 |
|
|
| 1.36 |
|
|
| 1.32 |
|
Denotes significance greater than 1.30, corresponds to –(log of Benjami-Hochberg corrected p-value <0.05.
Figure 4Gene targets enriched in Gene Ontology and KEGG cholesterol biosynthetic pathways.
(A) Collective analyses by DAVID and Ingenuity pathway tools indicated significant upregulation of sterol biosynthesis (cholesterol) in the placentae of Meishan breed. Using the KEGG cholesterol biochemical pathway as a template, we mapped expression pattern differences (yellow, upregulation in MS; blue, downregulation in MS) corresponding to placental expression breed differences at D65. The final catalytic step of cholesterol production is mediated by the reductase DHCR7, an imprinted gene [40]. (B) Bar graphs indicating relative quantitation by EvaGreen RT-qPCR of D65 placentae were used to determine gene expression intensities of a subset of cholesterol biosynthetic genes. Normalization across biological replicates and breed groups were performed using housekeeping gene RPS20. A two-tailed heteroscedastic Student t-test was used to report significance (p<0.05). Error bars reflect standard error of the mean for three placental samples after three repeated measurements of the same group (technical replicates).
Figure 5Temporal changes in cholesterol biosynthesis gene expression throughout gestation.
To visualize and identify patterns of gene expression, the KEGG cholesterol biosynthetic genes were plotted at each gestational time point (x-axis) using mean intensities (y-axis) of normalized microarray data. Arrows denote the metabolic flux through biochemical pathway: that is, the biochemical steps in which acetyl co-enzyme A is processed into cholesterol. A shaded grey box is overlaid for convenience to show the D45–D65 breed-specific cholesterol pattern.
Breed-specific microarray expression levels of sterol biosynthesis genes identified as enriched by Ingenuity Pathway Analysis.
| Gene | Gene Description | Pathway or Process | D25 MS Mean+StD | D25 WC Mean+StD | D45 MS Mean+StD | D45WC Mean+StD | D65 MS Mean+StD | D65WC Mean+StD | D85 MS Mean+StD | D85 WC Mean+StD | D105 MS Mean+StD | D105 WC Mean+StD | Breed Fold Change (MS-WC) |
| ABCA1 | atp-binding cassette, sub-family a (abc1), member 1 | cholesterol biosynthesis | 0.14±0.032 | 1.48±0.053 | 0.02±0.048 | 1.71±0.128 | 0.19±0.139 | 2.3±0.127 | 0.47±0.032 | 2.43±0.129 | 0.62±0.131 | 2.41±0.078 | -3.43 q <0 |
| APOF | apolipoprotein F | cholesterol biosynthesis | −0.09±0.091 | −0.38±0.091 | −0.2±0.052 | −0.48±0.097 | −0.28±0.223 | −0.56±0.164 | −0.16±0.046 | −0.67±0.071 | −0.39±0.074 | −0.6±0.151 | 1.24 q <1E-3 |
| CYB5R3 | cytochrome B5 reductase 3 | cholesterol biosynthesis | 2.26±0.061 | 1.87±0.139 | 1.32±0.092 | 1.92±0.108 | 1.69±0.085 | 2.06±0.116 | 1.99±0.097 | 2.37±0.02 | 2.47±0.18 | 2.73±0.006 | −1.2 q <3E-3 |
| CYP4B1 | cytochrome P450, family 4, subfamily b, polypeptide 1 | cholesterol biosynthesis | −0.28±0.099 | −0.27±0.047 | 1.46±0.188 | 0.48±0.063 | 0.25±0.387 | 0.55±0.269 | 1.22±0.259 | 0.25±0.062 | 1.6±0.274 | 0.55±0.09 | 1.48 q <1E-3 |
| CYP51A1 | cytochrome P450, family 51, subfamily a, polypeptide 1 | cholesterol biosynthesis | 1.89±0.157 | 1.26±0.115 | 3.17±0.089 | 2.98±0.083 | 3.18±0.299 | 2.66±0.301 | 3.07±0.101 | 2.56±0.077 | 2.8±0.149 | 2.27±0.033 | 1.38 q <1E-4 |
| CYP7B1 | cytochrome P450, family 7, subfamily b, polypeptide 1 | cholesterol biosynthesis | 0.92±0.165 | 1.44±0.081 | 2.65±0.039 | 2.8±0.026 | 1.83±0.284 | 2.3±0.034 | 1.29±0.236 | 1.43±0.259 | 0.72±0.116 | 0.86±0.135 | −1.21 q <0.05 |
| DHCR7 | 7-dehydrocholesterol reductase | cholesterol biosynthesis | 0.89±0.218 | 0.56±0.037 | 2.05±0.19 | 2.35±0.139 | 1.34±0.15 | 2.33±0.158 | 2.88±0.366 | 2.89±0.057 | 2.2±0.136 | 2.48±0.145 | −1.23 q <0.08 |
| EBP | emopamil binding protein (sterol isomerase) | cholesterol biosynthesis | 2.21±0.303 | 1.3±0.05 | 1.99±0.083 | 2.11±0.111 | 2.16±0.153 | 1.77±0.131 | 2.54±0.118 | 2.13±0.127 | 1.99±0.103 | 1.57±0.146 | 1.32 q <1E-3 |
| FABP4 | fatty acid binding protein 4 | cholesterol biosynthesis | −1.39±0.069 | −1.4±0.026 | −1.17±0.046 | −1.1±0.062 | −1.34±0.087 | −0.47±0.434 | −0.97±0.055 | −0.64±0.333 | −1.01±0.097 | −0.37±0.118 | −1.31 q <0.02 |
| FDFT1 | farnesyl-diphosphate farnesyltransferase 1 | cholesterol biosynthesis | 2.58±0.079 | 1.87±0.131 | 2.07±0.048 | 2.12±0.084 | 2.17±0.124 | 1.85±0.089 | 2.56±0.193 | 2.09±0.064 | 2.23±0.164 | 1.88±0.063 | 1.3 q <6E-4 |
| FDPS | farnesyl diphosphate synthase | cholesterol biosynthesis | 1.97±0.041 | 1.43±0.175 | 2.21±0.057 | 2.08±0.132 | 2.38±0.188 | 1.71±0.093 | 2.37±0.171 | 2.01±0.031 | 1.92±0.195 | 1.69±0.094 | 1.31 q <3E-4 |
| G6PD | glucose-6-phosphate dehydrogenase | cholesterol biosynthesis | 0.33±0.042 | 0.08±0.036 | 0.24±0.064 | −0.09±0.035 | 0.15±0.2 | 0.12±0.123 | 0.49±0.108 | −0.1±0.061 | −0.08±0.07 | −0.34±0.049 | 1.24 q <1E-4 |
| HMGCR | 3-hydroxy-3-methylglutaryl-coA reductase | cholesterol biosynthesis | −1.47±0.071 | −1.48±0.029 | −1.36±0.036 | −1.47±0.048 | −1.44±0.133 | −1.38±0.107 | −1.38±0.07 | −1.5±0.042 | −1.3±0.094 | −1.43±0.049 | 1.38 q <9E-4 |
| HMGCS1 | 3-hydroxy-3-methylglutaryl-coA synthase 1 | cholesterol biosynthesis | 1.59±0.118 | 0.81±0.052 | 2.33±0.171 | 2.25±0.122 | 2.62±0.237 | 1.86±0.258 | 2.7±0.181 | 2.14±0.095 | 2.15±0.185 | 1.65±0.056 | 1.45 q <3E-4 |
| HMGCS1 | 3-hydroxy-3-methylglutaryl-coa synthase 1 | cholesterol biosynthesis | −0.68±0.052 | −0.89±0.012 | 0.19±0.089 | −0.18±0.049 | 0.45±0.074 | −0.23±0.065 | 0.61±0.129 | 0±0.05 | 0.2±0.295 | −0.54±0.075 | 1.43 q <2E-8 |
| IDI1 | isopentenyl-diphosphate delta isomerase 1 | cholesterol biosynthesis | 2.93±0.109 | 2.39±0.039 | 3.44±0.108 | 3.25±0.144 | 3.64±0.2 | 2.86±0.229 | 3.64±0.049 | 3.24±0.083 | 3.23±0.062 | 2.74±0.072 | 1.41 q <1E-6 |
| INSIG1 | insulin induced gene 1 | cholesterol biosynthesis | 0.04±0.104 | −0.19±0.084 | −0.42±0.105 | −0.41±0.131 | −0.22±0.275 | −0.53±0.197 | −0.4±0.017 | −0.55±0.08 | −0.61±0.087 | −0.55±0.067 | 1.23 q <0.04 |
| LPL | lipoprotein lipase | cholesterol biosynthesis | −0.72±0.11 | −0.74±0.108 | 0.48±0.254 | −0.37±0.172 | −0.56±0.224 | −0.47±0.14 | −0.59±0.091 | −0.87±0.032 | −0.61±0.094 | −0.87±0.092 | 1.21 q <0.07 |
| MVD | mevalonate (diphospho) decarboxylase | cholesterol biosynthesis | 1.72±0.004 | 1.37±0.032 | 1.83±0.131 | 1.91±0.111 | 2.11±0.143 | 1.71±0.08 | 2.53±0.212 | 1.9±0.019 | 2.19±0.147 | 1.6±0.099 | 1.3 q <8E-4 |
| MVK | mevalonate kinase | cholesterol biosynthesis | 0.99±0.058 | 0.57±0.034 | 0.91±0.061 | 0.91±0.083 | 1.11±0.127 | 0.77±0.115 | 1.34±0.149 | 0.99±0.017 | 1.18±0.106 | 0.69±0.057 | 1.25 q <3E-5 |
| MVK | mevalonate kinase | cholesterol biosynthesis | 0.17±0.063 | −0.05±0.074 | −0.41±0.059 | −0.47±0.033 | −0.39±0.155 | −0.61±0.119 | −0.32±0.112 | −0.51±0.049 | −0.35±0.126 | −0.58±0.059 | 1.15 q <0.02 |
| NPC2 | niemann-pick disease, type C2 | cholesterol biosynthesis | 1.8±0.042 | 2.14±0.099 | 1.98±0.059 | 2.31±0.097 | 2.29±0.09 | 3.49±0.275 | 3.07±0.151 | 3.43±0.211 | 3.52±0.1 | 4.22±0.263 | −1.5 q <1E-5 |
| NR5A2 | nuclear receptor subfamily 5, group a, member 2 | cholesterol biosynthesis | 0.09±0.12 | −0.16±0.069 | −0.19±0.016 | −0.32±0.047 | −0.28±0.126 | −0.39±0.138 | −0.32±0.12 | −0.41±0.031 | −0.09±0.082 | −0.4±0.019 | 1.13 q <0.04 |
| NSDHL | NAD(P) dependent steroid dehydrogenase-like | cholesterol biosynthesis | 0.23±0.038 | 0.05±0.023 | 0.32±0.053 | 0.29±0.039 | 0.56±0.12 | 0.35±0.089 | 0.73±0.158 | 0.55±0.043 | 0.65±0.131 | 0.29±0.036 | 1.14 q <0.02 |
| NSDHL | NAD(P) dependent steroid dehydrogenase-like | cholesterol biosynthesis | 0.52±0.076 | 0.05±0.02 | 0.7±0.055 | 0.77±0.079 | 0.86±0.155 | 0.65±0.177 | 1.15±0.14 | 0.89±0.077 | 0.91±0.085 | 0.68±0.077 | 1.16 q <0.04 |
| OSBPL1A | oxysterol binding protein-like 1A | cholesterol biosynthesis | −0.59±0.08 | −0.64±0.06 | 0.21±0.077 | 1.05±0.087 | 0.33±0.13 | 0.88±0.17 | 0.43±0.055 | 0.79±0.16 | −0.05±0.159 | 0.42±0.126 | −1.34 q <2E-5 |
| PRKAA2 | protein kinase, amp-activated, alpha 2 catalytic subunit | cholesterol biosynthesis | −0.89±0.003 | −0.98±0.06 | −0.4±0.103 | −0.66±0.08 | −0.07±0.126 | −0.51±0.125 | −0.22±0.151 | −0.32±0.062 | −0.14±0.186 | −0.56±0.009 | 1.2 q <7E-3 |
| SC5DL | sterol-c5-desaturase -like | cholesterol biosynthesis | 0.87±0.074 | 0.3±0.216 | 1.66±0.117 | 1.43±0.172 | 2.11±0.346 | 0.9±0.229 | 1.68±0.118 | 1.17±0.087 | 1.24±0.186 | 0.59±0.055 | 1.56 q <8E-6 |
| SREBF2 | sterol regulatory element binding transcription factor 2 | cholesterol biosynthesis | 2.04±0.05 | 1.77±0.079 | 2.09±0.095 | 2.19±0.095 | 2.36±0.152 | 1.86±0.098 | 2.4±0.155 | 2.2±0.03 | 2.14±0.133 | 1.8±0.117 | 1.18 q <0.02 |
| TM7SF2 | transmembrane 7 superfamily member 2 | cholesterol biosynthesis | 0.32±0.361 | −0.11±0.051 | 1.61±0.226 | 1.91±0.184 | 2.36±0.109 | 1.32±0.143 | 3.11±0.171 | 2.09±0.091 | 2.07±0.206 | 1.08±0.223 | 1.57 q <4E-5 |
| ABCA1 | atp-binding cassette, sub-family a, member 1 | LXR/RXR activation | 0.14±0.032 | 1.48±0.053 | 0.02±0.048 | 1.71±0.128 | 0.19±0.139 | 2.3±0.127 | 0.47±0.032 | 2.43±0.129 | 0.62±0.131 | 2.41±0.078 | −3.43 q <0 |
| ACACA | acetyl-coA carboxylase alpha | LXR/RXR activation | 0.09±0.037 | −0.01±0.031 | −0.13±0.087 | −0.22±0.026 | −0.14±0.201 | −0.24±0.16 | −0.07±0.079 | −0.29±0.026 | −0.17±0.072 | −0.3±0.045 | 1.22 q <8E-5 |
| CCL2 | chemokine (c-c motif) ligand 2 | LXR/RXR activation | −0.56±0.085 | −0.45±0.262 | −0.65±0.021 | −0.66±0.029 | −0.66±0.102 | −0.53±0.144 | −0.45±0.105 | −0.45±0.133 | −0.66±0.127 | 0.81±0.373 | −1.27 q <0.02 |
| CYP4A11 | cytochrome P450, family 4, subfamily A, polypeptide 11 | LXR/RXR activation | −0.19±0.538 | −0.65±0.074 | −0.32±0.231 | −0.67±0.05 | −0.31±0.255 | −0.62±0.103 | 0.9±0.342 | −0.75±0.03 | −0.07±0.435 | −0.61±0.054 | 0.62 q <3E-3 |
| CYP4A22 | cytochrome P450, family 4, subfamily A, polypeptide 22 | LXR/RXR activation | −0.83±0.117 | −0.95±0.018 | −0.61±0.065 | −0.8±0.024 | −0.67±0.058 | −0.54±0.071 | −0.3±0.16 | −0.87±0.073 | −0.41±0.05 | −0.51±0.055 | 0.17 q <0.02 |
| FASN | fatty acid synthase | LXR/RXR activation | 1.59±0.061 | 1.03±0.051 | 1.17±0.174 | 1.35±0.08 | 1.33±0.292 | 0.88±0.212 | 1.15±0.049 | 0.84±0.064 | 0.5±0.125 | 0.54±0.18 | 1.27 q <8E-3 |
| HADH | fatty acid synthase hydroxylacyl-coA dehydrogenase | LXR/RXR activation | 2.03±0.051 | 2.17±0.094 | 1.84±0.101 | 2.1±0.103 | 1.69±0.129 | 2.21±0.224 | 2.09±0.15 | 2.34±0.073 | 1.97±0.118 | 2.25±0.033 | −1.22 q <8E-3 |
| LBP | lipopolysaccharide binding protein | LXR/RXR activation | −0.73±0.042 | −0.68±0.024 | −0.17±0.05 | −0.45±0.111 | 0.5±0.209 | −0.67±0.13 | 0.29±0.073 | −0.81±0.007 | 0.09±0.174 | −0.47±0.081 | 1.53 q <1E-13 |
| LY96 | lymphocyte antigen 96 | LXR/RXR activation | −0.65±0.055 | −0.27±0.035 | −0.58±0.019 | −0.56±0.081 | −0.45±0.069 | −0.09±0.258 | −0.29±0.098 | −0.13±0.013 | −0.31±0.098 | 0.25±0.137 | −1.23 q <3E-3 |
| LYCAT | lysocardiolipin acyltransferase 1 | LXR/RXR activation | −0.51±0.039 | −0.65±0.059 | 0.71±0.032 | −0.6±0.319 | 0.28±0.126 | 0.12±0.063 | 0.49±0.028 | 0.45±0.032 | 0.34±0.132 | −0.38±0.324 | 0.45 q <3E-4 |
| OSBPL10 | oxysterol binding protein-like 10 | LXR/RXR activation | −1.03±0.045 | −0.93±0.094 | −0.64±0.02 | −0.22±0.029 | −0.56±0.117 | −0.25±0.061 | −0.66±0.085 | −0.27±0.142 | −0.67±0.084 | −0.35±0.058 | −0.3 q <1.3E-5 |
| OSBPL3 | oxysterol binding protein-like 3 | LXR/RXR activation | −0.85±0.037 | −0.71±0.066 | −0.31±0.083 | −0.33±0.049 | −0.34±0.171 | 0.34±0.134 | −0.14±0.043 | 0.33±0.082 | 0.4±0.045 | 0.77±0.059 | −0.33 q <0.03 |
| OSBPL9 | oxysterol binding protein-like 9 | LXR/RXR activation | 2.61±0.174 | 2.94±0.238 | 1.76±0.055 | 2.24±0.205 | 2.01±0.065 | 2.26±0.31 | 2.13±0.011 | 2.33±0.061 | 1.75±0.097 | 2.13±0.124 | −0.31 q <4E-7 |
| PLTP | phospholipid transfer protein | LXR/RXR activation | 0.25±0.055 | 0.5±0.121 | −0.07±0.028 | 0.78±0.317 | −0.06±0.09 | 0.36±0.409 | 0.54±0.291 | 0.46±0.147 | −0.35±0.132 | 0.1±0.022 | −1.3 q <0.05 |
| PROM2 | prominin 2 | LXR/RXR activation | 0.74±0.277 | 0.62±0.043 | 2.63±0.198 | 2.71±0.073 | 2.83±0.322 | 2.07±0.173 | 2.33±0.111 | 1.98±0.085 | 1.68±0.131 | 1.14±0.197 | 0.34 q <0.04 |
| RXRG | retinoid x receptor, gamma | LXR/RXR activation | 0.02±0.021 | 0.02±0.045 | 0.08±0.022 | −0.07±0.044 | 0.04±0.108 | −0.35±0.136 | −0.38±0.094 | −0.42±0.029 | −0.28±0.076 | −0.35±0.044 | 1.15 q <3E-3 |
| STARD3 | star-related lipid transfer (start) domain containing 3 | LXR/RXR activation | 0.87±0.018 | 0.91±0.045 | 1.25±0.017 | 1.61±0.079 | 1.48±0.182 | 1.47±0.087 | 1.05±0.036 | 1.19±0.112 | 0.9±0.088 | 1.08±0.099 | −0.14 q <0.09 |
| TNFRSF1B | tumor necrosis factor receptor superfamily, member 1b | LXR/RXR activation | 0.74±0.057 | 0.85±0.095 | 0.67±0.069 | 0.84±0.05 | 0.83±0.043 | 1.03±0.15 | 1.02±0.062 | 1.13±0.068 | 1.4±0.033 | 1.79±0.176 | −1.14 q <0.03 |
Denotes significant at adjusted q-value <0.05.
Figure 6Biochemical analysis of cholesterol concentrations in swine placentae.
(A) Free and (B) esterified cholesterol concentrations were measured in swine placentae by the Amplex Red assay at each gestational interval. No differences in free or esterfied cholesterol concentrations were observed at D25. At D45, both free and esterified cholesterol levels showed significant differences. These differences in cholesterol concentration by breed were maintained throughout gestation at the sampled time points. Error bars reflect standard error of the mean for six placental samples with three repeated measurements of the same group (technical replicates).
Figure 7Differential expression of endothelial markers across gestation in swine placentae.
Canonical biomarkers specific to endothelial cells were used as a surrogate measure of placental vascularity. Biomarkers are plotted by gestational time with respect to normalized expression. Asterisks denote corrected multiple-testing significance (p<0.05) and crosses denote a trend (p<0.1). Multiple plots are shown for FLT1 and PECAM, and this reflects the gene estimate measurements for each of the multiple probe sets printed on the short-oligonucleotide array.
Figure 8Model of cholesterol utilization in swine placentae.
Combined, our results support differential cholesterol synthesis, transport and transcriptional activation in the placentae of two breeds of swine. Specifically, our results predict 1) increased cholesterol biosynthetic activity in Meishan placentae, 2) increased cholesterol efflux by transporters ABCA1 towards the fetal blood lumen in WC placentae and 3) increased gene expression by transcriptional activation of cholesterol enzymes mediated in part by SRE-binding proteins and RXR/LXR signaling in Meishan.